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Supervised Exercise Intervention
and Overall Activity in CKD
Mindy M. Pike1,2, Aseel Alsouqi1, Samuel A.E. Headley3, Katherine Tuttle4,5,
Elizabeth Elspeth Evans3, Charles M. Milch3, Kelsey Anne Moody3, Michael Germain6,
Thomas G. Stewart7, Loren Lipworth1,2, Jonathan Himmelfarb4, T. Alp Ikizler1 and
Cassianne Robinson-Cohen1
1Vanderbilt O’Brien Kidney Center, Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University
Medical Center, Nashville, Tennessee, USA; 2Division of Epidemiology, Department of Medicine, Vanderbilt University Medical
Center, Nashville, Tennessee, USA; 3Department of Exercise Science and Athletic Training, Springfield College, Springfield,
Massachusetts, USA; 4Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington,
Seattle, Washington, USA; 5Providence Medical Research Center, Providence Health Care, Spokane, Washington, USA;
6Department of Nephrology, Bay State Medical Center, Springfield, Massachusetts, USA; and 7Department of Biostatistics,
Vanderbilt University Medical Center, Nashville, Tennessee, USA
Introduction: Patients are often instructed to engage in multiple weekly sessions of exercise to increase
physical activity. We aimed to determine whether assignment to a supervised exercise regimen increases
overall weekly activity in individuals with chronic kidney disease (CKD).
Methods: We performed a secondary analysis of a pilot randomized 2  2 factorial design trial examining
the effects of diet and exercise (10%15% reduction in caloric intake, 3 supervised exercise sessions/wk,
combined diet restriction/exercise, and control). Activity was measured as counts detected by acceler-
ometer. Counts data were collected on all days for which an accelerometer was worn at baseline, month 2,
and month 4 follow-up. The primary outcome was a relative change from baseline in log-transformed
counts/min. Generalized estimating equations were used to compare the primary outcome in in-
dividuals in the exercise group and the nonexercise group.
Results: We examined 111 individuals randomized to aerobic exercise or usual activity (n ¼ 48 in the
exercise group and n ¼ 44 controls). The mean age was 57 years, 42% were female, and 28% were black.
Median overall adherence over all time was 73%. Median (25th, 75th percentile) counts/min over non-
supervised exercise days at months 2 and 4 were 237.5 (6.5, 444.4) for controls and 250.9 (7.7, 529.8) for
the exercise group (P ¼ 0.74). No difference was observed in the change in counts/min between the ex-
ercise and control groups over 3 time points (b [fold change], 0.96, 95% confidence interval [CI], 0.91, 1.02).
Conclusion: Engaging in a supervised exercise program does not increase overall weekly physical activity
in individuals with stage 3 to 4 CKD.
Kidney Int Rep (2020) 5, 1261–1270; https://doi.org/10.1016/j.ekir.2020.06.006
KEYWORDS: accelerometer; counts per minute; chronic kidney disease; exercise; physical activity; randomized
ª 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P
hysical activity confers a multitude of benefits that
may counteract the adverse metabolic environment
of kidney dysfunction. Among individuals with CKD,
greater physical activity has been associated with
better physical functioning, slower rates of kidney
function decline, and lower risks of cardiovascular
events and mortality.1–6 Concurrently, these
individuals are less likely than their counterparts with
preserved kidney function to achieve recommended
physical activity levels. As such, increasing regular
physical activity is considered an important target to
counteract the development of complications of CKD.
Although health care providers encourage increases
in physical activity levels by recommending regular
exercise sessions, adherence is often poor.7,8 More
intensive interventions involving supervised activity
may improve adherence. However, these exercise in-
terventions may account for only a small percentage of
total physical activity and may have little impact on
total physical activity levels, although this has not
been investigated extensively.
Correspondence: Cassianne Robinson-Cohen, Division of
Nephrology and Hypertension, Vanderbilt University Medical
Center, 2525 West End Avenue Suite 300, Nashville, Tennessee
37203, USA. E-mail: cassianne.robinson-cohen@vumc.org
Received 6 February 2020; revised 27 May 2020; accepted 8 June
2020; published online 15 June 2020
Kidney International Reports (2020) 5, 1261–1270 1261
CLINICAL RESEARCH
We recently reported the results of a pilot random-
ized clinical trial examining the efficacy, feasibility,
and safety of supervised exercise and calorie restriction
in patients with stage 3 to 4 CKD. In this secondary
analysis, we aimed to determine whether assignment to
a supervised exercise regimen would increase overall
weekly physical activity in individuals with CKD.
METHODS
Study Design
We performed a secondary analysis of a pilot ran-
domized 2  2 factorial design trial examining the ef-
fects of diet and exercise.9 We used the Consolidated
Standards of Reporting Trials (CONSORT) checklist
when writing our report. Details of the parent ran-
domized controlled trial have previously been
described.8 In brief, participants were randomized to 1
of 4 interventions, for a duration of 4 months: (i) di-
etary restriction (10%15% daily caloric restriction);
(ii) supervised exercise regimen (3 times/wk); (iii)
combined dietary restriction and supervised exercise
regimen; or (iv) control (usual exercise and diet)
(NCT01150851). Participants in the supervised exercise
group were scheduled to perform low-impact aerobic
exercise for 30 to 45 minutes, 3 times per week for 4
months. To provide variety, participants alternated
exercise with the use of a treadmill, elliptical cross-
trainer, Nu-Step cross-trainer, and recumbent station-
ary bicycle.
Inclusion criteria consisted of estimated glomerular
filtration rate (eGFR) 15 to 60 ml/min per 1.73 m2, age
18 to 75 years, body mass index (BMI) $25 kg/m2, life
expectancy $1 year, and the ability to understand and
to provide informed consent. Participants were
excluded for any acute inflammatory condition, preg-
nancy, high-dose antioxidant use, chronic use of anti-
inflammatory medication, significant cardiac or
vascular disease, significant occlusive atherosclerotic
disease or ischemic disease, significant physical immo-
bility or disabilities, type 1 diabetes mellitus or type 2
diabetes mellitus requiring insulin therapy, and history
of poor adherence to a medical regimen.8
The study was approved by the Institutional Review
Boards at participating sites (Vanderbilt University
Medical Center (VUMC), the Veterans Affairs Tennessee
Valley Healthcare System Nashville (VATVHS), Uni-
versity of Washington (UW), Providence Medical
Research Center (PMRC), and Springfield College (SC)).
All participants provided written informed consent
before study enrollment. The study began in October
2010 and was completed in February 2014. The safety
profile of the initial study was overseen by a Data
Safety Monitoring Board. A total of 122 participants
consented, 111 were randomized, 104 started interven-
tion, and 92 completed the original study (completed all
baseline, 2-month, and 4-month visits) (Figure 1).
Data Collection
Demographic, anthropometric, lifestyle, medication,
physical examination, and laboratory data were
collected at baseline (2 weeks prior to initiation of
intervention phase). Follow-up visits were conducted
at 2 months and 4 months. Hypertension and diabetes
were ascertained by self-report, and glomerular filtra-
tion rate (eGFR) was estimated by the 2012 cystatin C-
based Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI) equation.10
All participants were issued an ActiGraph GT3X
accelerometer (Actigraph, Fort Walton Beach, FL), a
pager-sized device powered by a small lithium battery.
Participants wore the accelerometer for 1 week after the
initial baseline visit and for 1 week either before or
after both the month 2 and month 4 study visits. The
accelerometer was attached to an elasticized belt and
worn on the right hip. Participants were instructed to
wear the accelerometer throughout the waking hours
except for instances when this was not feasible (e.g.,
during showering and swimming). The exercise group
participants were instructed to wear the accelerometers
during prescribed exercise sessions. The triaxial
accelerometer estimates the duration and intensity of
physical activity by capturing the magnitude of ac-
celeration (intensity) in 3 dimensions and then sum-
ming the magnitudes as counts per minute (higher
counts per minute indicate more physical activity).11
Validation for this instrument has been previously re-
ported.12 A nonwear period was defined as an interval
of $60 minutes of zero activity counts that contained
no more than 2 minutes of counts between 0 and 100. A
nonwear period ended with either a third minute of
activity counts >0 or a 1-minute activity count >100.11
Accelerometer data were available for up to 7 days at
baseline, month 2, and month 4 visits.
Statistical Analyses
A total of 111 participants who were randomized were
included in the intent-to-treat analysis (Figure 1). For
the purposes of this analysis, the “control” group was
defined as either the dietary restriction intervention
(n ¼ 28) or usual diet and exercise (n ¼ 26) partici-
pants. The intervention group was defined as either the
exercise regimen (n ¼ 27) or combined dietary re-
striction and exercise regimen (n ¼ 30) participants.
We tabulated baseline participant characteristics
according to intervention group. Counts/min were
calculated for each participant at baseline, month 2,
and month 4. For participants with missing baseline
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accelerometer data (n ¼ 19), single imputation informed
by age, race, gender, tobacco use, and comorbidities
was performed. Log-transformed accelerometry counts
per minute were modeled as the primary dependent
variable.
Linear regression was used to evaluate differences in
mean log-transformed counts/min at baseline, month 2,
and month 4, and over all time points, between the
exercise group and controls. Generalized estimating
equations with exchangeable correlations were used to
determine whether change per month of follow-up
differed between exercise and control groups. Ana-
lyses were completed including all accelerometer days
and, secondarily, excluding accelerometer days during
which individuals in the exercise group participated in
the supervised exercise intervention (i.e., restriction to
“nonexercise” days).
Sensitivity analyses were conducted to examine the
robustness of our findings. First, to examine the impact
among more physically active individuals, we stratified
by median baseline counts per minute and by baseline
percentage of sedentary time. Second, to examine the
impact of adherence to the exercise regimen (atten-
dance of supervised exercise sessions), we stratified
participants in the exercise group by median adherence
(73% adherence). Only participants who completed the
study (n ¼ 92) were included in the adherence ana-
lyses. Third, to examine differences in sedentary, light,
moderate, and vigorous activity, linear regression was
used to evaluate differences in mean log-transformed
minutes/day at baseline, month 2, and month 4, and
over all time points. Fourth, we stratified by gender.
Fifth, we examined the influence of caloric restriction
on activity by comparing the counts/min between the
usual diet and caloric restriction groups among par-
ticipants randomized to aerobic exercise.
Statistical analyses were conducted with Stata
version 14.2 (StataCorp, College Station, TX) and R
Studio (RStudio, PBC, Boston, MA).13 The nominal
level of significance was defined as P < 0.05 (2-sided).
RESULTS
A total of 111 individuals were randomized in the
original randomized controlled trial and were included
in this analysis (57 exercise group and 54 controls)
(Table 1). Most participants were male (58%), white
(67%), and hypertensive (90%). Participants with
diabetes comprised 25% of participants. Median (25th,
75th percentile) age was 59.5 years (49.0, 65.0 years) for
controls and 55.0 years (49.0, 61.0 years) for partici-
pants in the exercise group. Median (25th, 75th
percentile) baseline eGFR was 36.7 ml/min per 1.73 m2
(28.9, 50.4 ml/min per 1.73 m2) and 40.1 ml/min per
1.73 m2 (26.5, 51.3 ml/min per 1.73 m2) for control and
exercise groups, respectively.
At baseline, the mean number of days in which an
accelerometer was worn was 5.4 days for both the ex-
ercise and controls groups. At month 2, the mean
number of days in which an accelerometer was worn
was 6.3 days and 6.5 days for the exercise and control
groups, respectively. At month 4, the mean number of
days with an accelerometer was 4.3 days for controls
and 3.6 days for the exercise group (Figure 2).
Median (25th, 75th percentile) counts/min for all
accelerometer days at months 2 and 4 were 237.5 (6.5,
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Participants lost to follow-up were excluded in compliance
analyses.
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444.4) for controls and 354.5 (8.1, 531.0) for partici-
pants in the exercise group (P ¼ 0.38) (Table 2,
Figure 3). When including only nonexercise days in the
exercise group, no difference in counts/min was
observed between the control and exercise groups
(237.5 [interquartile range, 6.5, 444.4] vs. 250.9 [inter-
quartile range, 7.7, 529.8], respectively, P ¼ 0.74). No
statistically significant differences were observed in
counts/min for all accelerometer days between the
control and exercise groups at baseline, month 2, or
month 4 (Table 2, Figure 4). Similarly, no statistically
significant differences were observed when only non-
exercise days were included. The change per month in
counts/min for all accelerometer days and nonexercise
Table 1. Participant baseline characteristics, according to randomization to exercise intervention
Characteristic Overall (n [ 111) Control (n [ 54) Treatment (n [ 57)
Age, yr 57.0 (49.0, 63.0) 59.5 (49.0, 65.0) 55.0 (49.0, 61.0)
Gender
Female 47 (42.3) 22 (40.7) 25 (43.9)
Male 64 (57.7) 32 (59.3) 32 (56.1)
Race
Black 31 (27.9) 17 (31.5) 14 (24.6)
White 74 (66.7) 35 (64.8) 39 (68.4)
Other 6 (5.4) 2 (3.7) 4 (7.0)
Caloric restriction 58 (52.3) 28 (51.9) 30 (52.6)
Current tobacco use 10 (9.0) 4 (7.4) 6 (10.5)
Body mass index, kg/m2 33.0 (28.8, 37.3) 33.7 (29.6, 38.8) 32.3 (28.5, 36.2)
Prevalent disease
Hypertension 100 (90.1) 48 (88.9) 52 (91.2)
Diabetes 28 (25.2) 14 (25.9) 14 (24.6)
Congestive heart failure 5 (4.5) 2 (3.7) 3 (5.3)
Myocardial infarction 2 (1.8) 0 (0.0) 2 (3.5)
Coronary artery disease 6 (5.4) 2 (3.7) 4 (7.0)
eGFR, ml/min per 1.73 m2 38.0 (28.1, 50.4) 36.7 (28.9, 50.4) 40.1 (26.5, 51.3)
Systolic BP, mm Hg 131 (115, 142) 132 (117, 142) 129 (114, 141)
Diastolic BP, mm Hg 78 (72, 84) 78 (72, 84) 78 (70, 85)
Light activity, min/d 155.9 (74.3, 225.9) 149.1 (63.9, 216.9) 163.9 (75.6, 228.0)
Moderate activity, min/d 10.7 (1.9, 25.6) 8.3 (1.0, 20.9) 12.4 (4.0, 25.7)
Vigorous activity, min/d 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1)
Sedentary time, min/d 498.3 (286.3, 618.4) 560.7 (309.4, 652.3) 446.4 (286.3, 586.6)
Baseline accelerometer days 7 (5, 7) 7 (5, 7) 7 (5, 7)
Month 2 accelerometer days 7 (6.5, 7) 7 (7, 7) 7 (6, 7)
Month 4 accelerometer days 5 (0, 7) 5 (0, 7) 5 (0, 7)
Data are n (%) or median (25th, 75th percentile). BP, blood pressure.
Figure 2. Mean days that accelerometer was worn at baseline, month 2, and month 4 for controls and exercise groups.
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days was 4% lower in the exercise group relative to
that in the controls (95% CI ¼ 9% lower – 2% higher)
(Table 2).
No differences were found for baseline, month 2,
month 4, counts/min over months 2 and 4, or change in
counts/min between control and exercise groups
Table 2. Counts per minute for controls and treatment group
Time point
Nonexercise days All accelerometer days
Control (n [ 44) Treatment (n [ 48) P value Control (n [ 44) Treatment (n [ 48) P value
Baseline 250.0 (7.2, 460.6) 344.3 (12.4, 507.2) 0.281 250.0 (7.2, 460.6) 344.3 (12.4, 507.2) 0.281
Mo 2 247.2 (8.9, 447.3) 378.8 (9.0, 562.5) 0.880 247.2 (8.9, 447.3) 378.8 (7.4, 645.9) 0.639
Mo 4 257.5 (6.2, 467.3) 201.0 (6.2, 527.2) 0.985 257.5 (6.2, 467.3) 319.4 (8.7, 566.2) 0.718
Mo 2 and 4 237.5 (6.5, 444.4) 250.9 (7.7, 529.8) 0.740 237.5 (6.5, 444.4) 354.5 (8.1, 531.0) 0.381
Baseline to mo 2 –1.5 (–53.5, 26.7) 1.9 (–29.4, 39.2) 0.863 –1.5 (–53.5, 26.7) 0.9 (–11.1, 83.6) 0.611
Baseline to mo 4 –1.3 (–74.0, 5.6) –2.1 (–59.8, 2.5) 0.319 –1.3 (–74.0, 5.6) 2.3 (–19.1, 41.2) 0.868
Change/mo Ref 0.96 (0.91, 1.02) 0.208 Ref 0.96 (0.91, 1.02) 0.197
Ref, Reference.
Data are median (25th, 75th percentile) or b (95% confidence interval). “All accelerometer days” includes all days on which an accelerometer was worn. “Nonexercise days” includes
only accelerometer days on which individuals in the exercise group did not participate in the exercise intervention.
Figure 3. Boxplot of counts/min over month 2 and month 4 for controls and exercise groups for (a) nonexercise days and (b) all accelerometer
days.
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among participants below the median activity level
(counts/min #345) (Table 3). In the group with base-
line counts/min above median, counts/min did not
differ between control and exercise groups for all
accelerometer days (434.3 [interquartile range, 383.0,
557.7] vs. 531.0 [interquartile range, 450.5, 707.0],
respectively, P¼0.58). Similarly, no statistically sig-
nificant differences were observed when only non-
exercise days were included for those with baseline
counts/min above the median. The change per month
in counts/min for all accelerometer days in participants
with above-median counts/min was 4% lower in the
exercise group relative to the controls (95% CI, 15%
lower – 9% higher). In participants with below-median
counts/min, for all accelerometer days, the change per
month was 13% lower in the exercise group relative to
controls (95% CI, 33% lower – 14% higher; Table 3).
Participants with less than 73% adherence to the ex-
ercise intervention were younger and more likely to be
black and to have hypertension (Supplemental Table S1).
The median eGFR was higher in participants with more
than 73% adherence. Counts/min at baseline, month 2,
and month 4 for controls and each adherence group are
shown in Table 4. Minutes/d in sedentary, light, mod-
erate, and vigorous activity at baseline, month 2, and
month 4 are shown in Supplemental Table S2. Counts/
min at baseline, month 2, and month 4 stratified by
baseline percentage of sedentary time are shown in
Figure 4. Boxplot of counts/min at baseline, month 2, and month 4 for controls and exercise groups for (a) nonexercise days and (b) all
accelerometer days.
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Supplemental Table S3. Counts/min stratified by gender
are shown in Supplemental Table S4. No differences were
found for baseline, month 2, month 4, counts/min over
months 2 and 4, or change in counts/min between control
and exercise groups stratified by percentage of sedentary
time or gender. When stratified by dietary restriction, no
differences in counts/min were found between the usual
diet and caloric restriction groups among those in the
exercise group.
DISCUSSION
In this study, we determined whether total weekly
physical activity over a 4-month period increased with
a supervised exercise intervention in patients with
moderate-to-severe CKD. Engaging in this exercise
intervention did not appreciably increase overall
weekly physical activity in the study participants. No
differences in counts per minute or change per month
were found at any time point between the control and
exercise groups.
Patients with chronic diseases benefit from engaging
in healthy lifestyle behaviors. Recent studies have
shown that higher physical activity levels are associ-
ated with lower risk of CKD and slower decline in
eGFR.14–20 The American Heart Association (AHA)
gives practical guidance for exercise and physical ac-
tivity, recommending moderate-intensity exercise for
Table 3. Counts per minute for controls and treatment group stratified by baseline median counts/min
Time point
Median £345 Median >345
Control (n [ 25) Treatment (n [ 19) P value Control (n [ 26) Treatment (n [ 22) P value
Nonexercise days
Baseline 53.0 (4.7, 242.1) 38.5 (8.3, 211.0) 0.648 531.6 (458.8, 668.0) 528.0 (441.9, 713.9) 0.993
Mo 2 12.9 (3.7, 237.9) 9.3 (5.9, 183.9) 0.660 451.1 (326.9, 624.9) 576.5 (471.4, 739.3) 0.918
Mo 4 10.3 (3.3, 173.2) 8.2 (4.7, 133.1) 0.819 466.8 (370.2, 530.5) 535.9 (427.5, 598.3) 0.229
mo 2 and 4 10.4 (3.6, 200.9) 8.3 (5.2, 163.0) 0.980 434.3 (383.0, 557.7) 532.4 (502.2, 637.7) 0.444
Baseline–mo 2 –0.9 (–22.3, 3.9) 1.9 (–4.2, 5.6) 0.764 –19.6 (–182.5, 95.4) –2.1 (–75.3, 68.0) 0.994
Baseline–mo 4 –0.2 (–38.6, 1.9) –0.7 (–2.0, 5.0) 0.941 –53.3 (–105.8, 42.5) –57.6 (–118.3, –2.7) 0.195
Change/mo Ref 0.87 (0.67, 1.13) 0.312 Ref 0.96 (0.85, 1.10) 0.567
All accelerometer days
Baseline 53.0 (4.7, 242.1) 38.5 (8.3, 211.0) 0.648 531.6 (458.8, 668.0) 528.0 (441.9, 713.9) 0.993
Mo 2 12.9 (3.7, 237.9) 7.4 (5.5, 183.9) 0.776 451.1 (326.9, 624.9) 618.2 (461.4, 747.1) 0.766
Mo 4 10.3 (3.3, 173.2) 8.9 (6.2, 133.1) 0.539 466.8 (370.2, 530.5) 566.3 (464.3, 600.6) 0.292
Mo 2 and 4 10.4 (3.6, 200.9) 11.1 (6.2, 163.0) 0.727 434.3 (383.0, 557.7) 531.0 (450.5, 707.0) 0.583
Baseline–mo 2 –0.9 (–22.3, 3.9) 0.3 (–4.2, 39.2) 0.584 –19.6 (–182.5, 95.4) 16.2 (–53.9, 122.4) 0.836
Baseline–mo 4 –0.2 (–38.6, 1.9) 2.3 (–0.8, 16.9) 0.258 –53.3 (–105.8, 42.5) –7.9 (–125.8, 80.6) 0.249
Change/mo Ref 0.87 (0.67, 1.14) 0.314 Ref 0.96 (0.85, 1.09) 0.559
Ref, Reference.
Data are median (25th, 75th percentile) or b (95% confidence interval). “All accelerometer days” includes all days on which an accelerometer was worn. “Nonexercise days” includes
only accelerometer days on which individuals in the exercise group did not participate in the exercise intervention.
Table 4. Counts per minute for controls and treatment group stratified by adherence
Time point Control Adherence <73% P value Control Adherence ‡73% P value
Nonexercise days
Baseline 276.0 (6.1, 501.7) 312.2 (66.7, 441.9) 0.247 276.0 (6.1, 501.7) 353.5 (6.4, 533.9) 0.806
Mo 2 266.3 (12.0, 449.2) 365.1 (96.6, 630.3) 0.540 266.3 (12.0, 449.2) 415.1 (8.1, 590.6) 0.710
Mo 4 283.2 (6.5, 467.8) 163.0 (11.2, 527.2) 0.718 283.2 (6.5, 467.8) 394.7 (6.7, 550.1) 0.899
Mo 2 and 4 259.4 (6.9, 444.4) 250.9 (55.1, 536.6) 0.374 259.4 (6.9, 444.4) 399.0 (8.0, 532.4) 0.871
Baseline–mo 2 –1.2 (–42.6, 28.2) 14.8 (–8.3, 66.0) 0.106 –1.2 (–42.6, 28.2) 2.4 (–9.3, 56.6) 0.429
Baseline–mo 4 –0.6 (–61.0, 7.4) –1.3 (–47.0, 38.4) 0.655 –0.6 (–61.0, 7.4) –1.9 (–57.6, 2.4) 0.918
Change/mo Ref 0.98 (0.93, 1.02) 0.311 Ref 0.99 (0.90, 1.08) 0.742
All accelerometer days
Baseline 276.0 (6.1, 501.7) 312.2 (66.7, 441.9) 0.247 276.0 (6.1, 501.7) 353.5 (6.4, 533.9) 0.806
mo 2 266.3 (12.0, 449.2) 378.8 (183.9, 737.4) 0.260 266.3 (12.0, 449.2) 431.9 (7.3, 590.6) 0.652
mo 4 283.2 (6.5, 467.8) 163.0 (25.6, 566.4) 0.603 283.2 (6.5, 467.8) 427.3 (8.8, 570.7) 0.783
mo 2 and 4 259.4 (6.9, 444.4) 349.1 (99.0, 566.4) 0.188 259.4 (6.9, 444.4) 423.6 (6.6, 523.1) 0.845
Baseline–mo 2 –1.2 (–42.6, 28.2) 37.4 (–5.6, 156.0) 0.018 –1.2 (–42.6, 28.2) 0.7 (–4.2, 56.6) 0.674
Baseline–mo 4 –0.6 (–61.0, 7.4) 16.9 (–0.8, 54.3) 0.797 –0.6 (–61.0, 7.4) 1.0 (–11.0, 48.5) 0.429
Change/mo Ref 1.01 (0.93, 1.09) 0.869 Ref 1.01 (0.92, 1.10) 0.844
Ref, Reference.
Data are median (25th, 75th percentile). “All accelerometer days” includes all days in which an accelerometer was worn. “Nonexercise days” include only accelerometer days on which
individuals in the exercise group did not participate in the exercise intervention.
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150 min/wk or 75 min/wk of vigorous activity, and
routine counseling in health care visits about exercise
and activity. For adults unable to meet the minimum
recommendations, the AHA mentions that engaging in
some moderate or vigorous physical activity, even if
under the recommended amount, is beneficial.21 Health
care providers often recommend exercise to patients in
the hope that physical activity levels will increase. Our
findings indicate that when patients with CKD partic-
ipated in a supervised exercise program for 4 months,
no differences in overall weekly physical activity
existed between those in the exercise and control
groups. In addition, participants in this study were not
encouraged to increase activity outside of the exercise
sessions. The implications of these findings are that
activity levels may not change outside of a supervised
exercise intervention in patients with CKD, and that,
when recommending exercise, patients should addi-
tionally be counseled on increasing their habitual level
of activity.
Data from the 2016 National Health Interview Sur-
vey from the Centers for Disease Control and Preven-
tion suggest that only 21.7% of adults in the United
States meet physical activity guidelines for both aero-
bic and strengthening activity.22 Individuals with
chronic disease are less likely to adhere to healthy
lifestyle guidelines. In a review on the effect of pre-
scribed exercise on nonexercise activity, Washburn
et al. found that compliance in exercise programs
ranged from 83% to 100%.23 Adherence to exercise
interventions differs for older individuals and those
with chronic diseases. For older individuals in ran-
domized trials of exercise, adherence ranged from 25%
to 76%.24–27 In a review of exercise training in adults
with CKD, the reported range of adherence to exercise
was 58% to 100%.28 The median adherence to the
exercise intervention in our study was 73%. Compared
to trials with healthier individuals, adherence in our
study was lower, but it was comparable to that in
populations of older individuals with chronic condi-
tions. Our findings suggest that even when controls
were compared to only those participants with greater
than 73% adherence, no differences were seen in
overall physical activity levels over 4 months of
monitoring.
Why the exercise intervention did not produce
increased overall weekly physical activity in our
study is not fully clear. In a review of the effect of
exercise on physical activity in adults, Melanson
suggests that regular exercise leads to compensatory
changes, such as an increase in sedentary time,
which may attenuate an increase in physical activ-
ity.29 Previous studies have reported mixed results
when examining whether compensatory sedentary
behaviors might negate some of the increases in
physical activity levels of individuals on exercise
regimens.30–36 The results from the present analysis
were consistent, and no differences were observed
even when all accelerometer days were included in
the analysis. Participants might have viewed the
exercise intervention as meeting their “requirement”
for healthy behaviors, and thus were less active at
other times. A review by Hannan and Bronas sug-
gests that in patients with CKD, fatigue or lack of
energy is a primary reason for avoidance of exercise.7
Additional recovery time may have been necessary to
recuperate from the exercise intervention, which
could lower activity on non-exercise days. Partici-
pants randomized to usual activity also might have
increased their activity because of the presence of an
accelerometer. A meta-analysis of the effect of
wearing accelerometers on physical activity and
weight found that accelerometer use only had small
positive effects on activity levels, but that these
small levels were not clinically relevant.37 In our
study, the small positive effects of accelerometers on
activity would be present in both the usual activity
and exercise groups.
The current study has several strengths. First, multiple
days of accelerometer data were collected for each
participant, and data were adjusted for wear time to
standardize the measurement. Counts per minute in this
study are representative of physical activity that actually
occured over a given week. Second, the exercise program
was supervised by clinical exercise physiologists and was
personalized to the participants’ physiological capabil-
ities. Limitations of the study also exist. First, following
an exercise regimen is often difficult for individuals to do
long term. Second, participants in both the usual activity
and exercise groups were asked to wear accelerometers to
measure activity, which may have affected behavior.
Participants in the control group may have increased
their weekly activity because of the wearing of an
accelerometer. In addition, our study group may not fully
represent the CKD community at large. Finally, we did
not collect details of daily activities to provide data for
mechanistic insights.
In conclusion, a supervised exercise program did
not noticeably increase overall weekly physical ac-
tivity in patients with moderate-to-severe CKD.
Although exercise regimens are often recommended,
participation in enjoyable activities such as sports,
hobbies, and recreational activities may prove more
effective long term to increase physical activity.
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